-
Article
Open AccessMetabolic profiling stratifies colorectal cancer and reveals adenosylhomocysteinase as a therapeutic target
The genomic landscape of colorectal cancer (CRC) is shaped by inactivating mutations in tumour suppressors such as APC, and oncogenic mutations such as mutant KRAS. Here we used genetically engineered mouse model...
-
Article
Open AccessOncogenic BRAF, unrestrained by TGFβ-receptor signalling, drives right-sided colonic tumorigenesis
Right-sided (proximal) colorectal cancer (CRC) has a poor prognosis and a distinct mutational profile, characterized by oncogenic BRAF mutations and aberrations in mismatch repair and TGFβ signalling. Here, we de...
-
Article
The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer
Oncogenic KRAS mutations and inactivation of the APC tumor suppressor co-occur in colorectal cancer (CRC). Despite efforts to target mutant KRAS directly, most therapeutic approaches focus on downstream pathways,...
-
Article
Open AccessRASSF1A uncouples Wnt from Hippo signalling and promotes YAP mediated differentiation via p73
Transition from pluripotency to differentiation is a pivotal yet poorly understood developmental step. Here, we show that the tumour suppressor RASSF1A is a key player driving the early specification of cell f...
-
Article
Open AccessPerfused Three-dimensional Organotypic Culture of Human Cancer Cells for Therapeutic Evaluation
Pharmaceutical research requires pre-clinical testing of new therapeutics using both in-vitro and in-vivo models. However, the species specificity of non-human in-vivo models and the inadequate recapitulation of ...
